Drug Pricing Reform: Now It Is HHS Secretary Becerra’s Turn
Executive Summary
After months of reticence about his Administration's plans for tackling drug pricing, Biden's executive order offers some clues about what might be in store and what kind of timeline they are working with.
You may also be interested in...
Biosimilars Forum Calls For Further Action On Biden’s Competition Order
Generics Bulletin sits down with Biosimilars Forum executive director Julie Reed to discuss preparing the HHS for Humira biosimilars, what more the agency could do for the industry and the Forum’s priorities over the next year.
CMS Innovation Center Exploring ‘Array’ Of Cost-Lowering Medicare Payment Models
CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.
White House Reticent On Drug Pricing Regulatory Plan With Legislative Efforts In Motion
HHS plan to be publicly released in coming weeks, White House official says. Meanwhile the US House passed a resolution clearing the way for consideration of a second infrastructure package that could include major drug pricing reforms such as Medicare price negotiation as cost offsets.